PF-562271 besylate is a chemical compound that has gained attention in both the scientific community and pharmaceutical industry for its potential health benefits. This product is also known as PF562271 or CAS number 939791-38-5.
Chemical name: The chemical name of PF-562271 is 6-(2,6-dichlorobenzo[d]oxazol-5-yl)-2, 3-dimethoxyquinoxaline.
Molecular formula: The molecular formula of PF-562271 is C17H12Cl2N4O3.
Formula weight: The formula weight of PF-562271 is 399.21 g/mol.
CAS No: The CAS number of PF-562271 is 939791-38-5.
Top ten keywords from Google and Synonyms:
- Cancer treatment
- Anti-tumor properties
- Kinase inhibitor
- Cell proliferation
- Metabolic disorders
- Small molecule inhibitor
Synonyms: PF-562,271, PF-0562271, Besylate, quinoxaline derivative.
Health benefits of this product: Studies have suggested that PF-562271 may have several health benefits, including its ability to act as a kinase inhibitor, which can help treat cancer and other diseases associated with abnormal cell growth. However, further research is required to confirm these health benefits.
Potential effects: PF-562271 besylate has been shown to inhibit various key kinases, leading to an inhibition of cell proliferation and an increase in apoptosis (programmed cell death). It has also been found to possess anti-inflammatory properties and could potentially be used to treat metabolic disorders such as diabetes.
Product mechanism: PF-562271 works by inhibiting multiple key kinases, including FAK (focal adhesion kinase), Pyk2 (proline-rich tyrosine kinase 2), and Aurora kinase A/B. Inhibiting these kinases leads to cell cycle arrest, decreased cell migration, and increased apoptosis.
Safety: While PF-562271 besylate has demonstrated promising results in preclinical studies, it is still undergoing clinical trials to determine its safety and efficacy. At present, there are no FDA-approved drugs containing PF-562271 besylate.
Side effects: As with any medication, some side effects may occur when taking PF-562271 besylate. Currently, limited data is available about the side effects of this product.
Dosing information: The dosage of PF-562271 besylate will vary depending on the condition being treated, the patient's age, and other factors. As previously mentioned, this product is currently undergoing clinical trials, and dosing information is not yet publicly available.
Conclusion: In conclusion, PF-562271 besylate is a promising new product with potential health benefits, including its ability to act as a kinase inhibitor, which could help treat cancer and other diseases associated with abnormal cell growth. While additional research is necessary to confirm these benefits, early studies show promise. However, more information is still required about the safety and side effects of this compound. Future research may provide valuable insights into the potential uses of PF-562271 besylate and how it can be used to improve human health